药物临床试验登记信息显示，深圳信立泰药业股份有限公司的评价不同剂量SAL0140片治疗2种或3种及 以上药物治疗且未控制的高血压患者的有效性和安全性的随机、双盲、安慰剂对照、多中心的Ⅱ期临床 研究已启动。临床试验登记号为CTR20254681，首次公示信息日期为2025年11月25日。 该药物剂型为片剂，用法为口服。本次试验主要目的为评价不同剂量SAL0140片治疗未控制的高血压患 者的有效性；次要目的为评价不同剂量SAL0140片治疗未控制的高血压患者的安全性，以及评价 SAL0140在未控制的高血压患者中的药代动力学特征。 风险提示：市场有风险，投资需谨慎。本文为AI大模型基于第三方数据库自动发布，任何在本文出现 的信息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不 构成个人投资建议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核 验，因此本文内容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问， 请联系biz@staff.sina.com.cn。 责任编辑：小浪快报 本次试验主要终点指标包括双盲治疗期结束平均诊室坐位 ...

Core Insights - The report highlights a significant increase in the performance of the stock market, with the Shanghai Composite Index rising by 1.14% to close at 3843.6 points, and the ChiNext Index experiencing a notable increase of 3.82% [3][8] - The report emphasizes the strong performance of specific sectors, particularly semiconductors, communication equipment, and electronic chemicals, which have shown substantial gains [8] - The overall market sentiment has improved, with over 2800 stocks rising and more than 60 stocks hitting the daily limit up, indicating a recovery in market confidence [8] Domestic Financial Market - The report provides a summary of key financial indices, including the Shanghai Composite Index at 3843.6 with a 1.14% increase, and the Shenzhen Component Index at 12571.37 with a 2.25% increase [3] - The report notes a decrease in trading volume, with the total turnover of the Shanghai and Shenzhen markets reaching 29,708 billion, down by 1,948 billion from the previous day [8] Macro News Summary - The Ministry of Commerce announced the final review of anti-dumping measures on phenol imports from the US, EU, South Korea, Japan, and Thailand [5] - As of the end of July, the total local government debt in China reached 5,276.27 billion, with general debt at 1,724.83 billion and special debt at 3,551.44 billion [5] - The Central Committee and State Council are establishing a sustainable financing system for urban construction and operation, leveraging the bond and stock markets [5] Industry Dynamics - Xiaomi has invested in a core component manufacturer for robotics, with institutions optimistic about the acceleration of the industry chain, highlighting related stocks such as Top Group (601689) and Mingzhi Electric (603728) [6] - The global satellite IoT connection count is expected to grow at a compound annual growth rate of 23.8% by 2030, with related stocks including Huali Chuantong (300045) and China Satellite (600118) [6] - The report mentions the expected increase in shipments of high-density power cabinets, which will drive new growth in AI data centers, with related stocks including Huadian Co. (002463) and Yuanjie Technology (688498) [6] Company Focus - Shenzhen South Circuit (002916) reported a 29.21% year-on-year increase in PCB business revenue for the first half of 2025, reaching 6.274 billion, with a gross margin increase of 3.05 percentage points [7] - Shanghai Xinyang (300236) saw a 126% year-on-year increase in net profit, driven by significant growth in sales of key materials for integrated circuit manufacturing [7] - Zhongtian Technology (600522) is developing a 224G foamed FEP high-speed copper cable, expected to enter mass production in the fourth quarter [7] - Xinlitai (002294) has received approval for clinical trials of its self-developed SAL0140, aimed at treating chronic kidney disease [7]

证券日报网讯 8月28日晚间，信立泰发布公告称，近日，公司收到国家药品监督管理局核准签发的受理 通知书，公司自主研发的创新小分子药物SAL0140片（项目代码：SAL0140）临床试验申请获得受理。 （编辑 楚丽君） ...

SAL0140是公司具有自主知识产权的醛固酮合酶抑制剂，拟开发适应症包括未控制高血压(包括难治性 高血压)、慢性肾脏病(CKD)等。目前，SAL0140(未控制高血压)正处于I期临床阶段。 格隆汇8月28日丨信立泰(002294.SZ)公布，近日，深圳信立泰药业股份有限公司收到国家药品监督管理 局核准签发的受理通知书，公司自主研发的创新小分子药物SAL0140片(项目代码：SAL0140)临床试验 申请获得受理。 ...

信立泰（002294）(002294.SZ)发布公告，近日，公司收到国家药品监督管理局核准签发的受理通知 书，公司自主研发的创新小分子药物SAL0140片(项目代码：SAL0140)临床试验申请获得受理。 SAL0140若能研发成功并获批上市，将有望为更多细分领域的高血压患者及CKD患者有针对性地提供新 的用药选择，满足未被满足的临床需求，并进一步丰富公司慢病领域的创新产品管线。 SAL0140是公司具有自主知识产权的醛固酮合酶抑制剂，拟开发适应症包括未控制高血压(包括难治性 高血压)、慢性肾脏病(CKD)等。目前，SAL0140(未控制高血压)正处于I期临床阶段。 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for the clinical trial application of its innovative small molecule drug SAL0140, which targets uncontrolled hypertension and chronic kidney disease [1] Group 1: Product Development - SAL0140 is a proprietary aldosterone synthase inhibitor developed by the company [1] - The drug is currently in Phase I clinical trials for the indication of uncontrolled hypertension [1] - If successful, SAL0140 is expected to provide new treatment options for patients with uncontrolled hypertension and chronic kidney disease, addressing unmet clinical needs [1] Group 2: Market Potential - The development of SAL0140 will enrich the company's pipeline of innovative products in the chronic disease sector [1] - The targeted indications for SAL0140 include resistant hypertension and chronic kidney disease, which represent significant market opportunities [1]

人民财讯8月28日电，信立泰（002294）8月28日晚间公告，近日，公司收到国家药品监督管理局核准签 发的受理通知书，公司自主研发的创新小分子药物SAL0140片(项目代码：SAL0140)临床试验申请获得 受理。公司本次提交的申请为SAL0140用于治疗慢性肾脏病(CKD)的临床试验申请。 ...